Persistent antibody responses but declining cytotoxic T-lymphocyte responses to multiple human immunodeficiency virus type 1 antigens in a long-term nonprogressing individual with a defective p17 proviral sequence and no detectable viral RNA expression
- PMID: 9525685
- PMCID: PMC109859
- DOI: 10.1128/JVI.72.4.3472-3474.1998
Persistent antibody responses but declining cytotoxic T-lymphocyte responses to multiple human immunodeficiency virus type 1 antigens in a long-term nonprogressing individual with a defective p17 proviral sequence and no detectable viral RNA expression
Abstract
Long-term nonprogressor AD-18 has been infected with human immunodeficiency virus type 1 (HIV-1) for at least 16 years. During the past 5 years, he has had undetectable levels of plasma viremia, and HIV-1 cannot be isolated from him. Sequencing of proviral DNA indicates that the only HIV-1 sequences that can be identified in AD-18 have gross defects in the p17-encoding regions of the gag gene (Y. Huang, L. Zhang, and D. D. Ho, Virology 240:36-49, 1998). However, AD-18 has strong, sustained antibody responses to several HIV-1 antigens, including p17. Cytotoxic T-lymphocyte responses to Env and Gag antigens have gradually diminished over the past 4 years, at a time when the titers of antibodies to the same proteins have remained stable. We discuss what these observations might mean for the generation and maintenance of immunological memory.
Figures


References
-
- Ahmed R, Gray D. Immunological memory and protective immunity: understanding their relation. Science. 1996;272:54–60. - PubMed
-
- Bachmann M F, Kündig T M, Odermatt B, Hengartner H, Zinkernagel R M. Free recirculation of memory B cells versus antigen-dependent differentiation to antibody forming cells. J Immunol. 1994;153:3386–3397. - PubMed
-
- Binley J M, Markowitz M, Cao Y, Hurley A, Ho D D, Moore J P. Abstracts of the 4th Conference on Retroviruses and Opportunistic Infections. 1997. Differential regulation of the antibody responses to gag and env proteins of HIV-1; effects of combination antiviral therapy, abstr. 384.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous